novel peptide

Monogram Biosciences, Inc. (NASDAQ: MGRM) 169% HIGHER; Laboratory Corporation of America Holdings (NYSE: LH) and Monogram have entered into a definitive agreement and plan of merger under which LabCorp will acquire all of the outstanding shares of Monogram in a cash tender offer for $4.55 per share for an implied total equity value of approximately $106.7 million, or a total enterprise value of approximately $155 million at March 31, 2009, including net indebtedness.

Compugen Ltd.

Compugen Ltd. (NASDAQ: CGEN) 45.5% HIGHER; announced that CGEN-25007, a novel peptide antagonist of gp96 with potent anti-inflammatory activity, has shown positive therapeutic effects in an animal model of inflammatory bowel disease, a commonly used term covering ulcerative colitis and Crohn's disease. Click here for the full report.